Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study reveals whether a simple scope test alters cancer care

NCT ID NCT06440174

Knowledge-focused Sponsor: University Hospital Southampton NHS Foundation Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study observes 160 adults with oesophageal cancer to see if an endoscopic ultrasound (EUS) changes their treatment plan after standard scans. Researchers will also interview patients and doctors to understand their views on using EUS. The goal is to learn when this test is most helpful, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients will be recruited through MDTs at participating secondary care centres in the UK. Those deemed suitable will be approached by their care team to take part.

Ages

16 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients aged 16 or above with first diagnosis of biopsy-confirmed oesophageal cancer. 2. Referred for EUS examination as part of standard of care investigations. 3. Tumour location in the oesophagus, or gastro-oesophageal junction (Siewert types I-III) 4. MDT decision that patient is potentially curable with radical treatment (e.g., endoscopic treatment, surgery +/- neoadjuvant therapy, or definitive chemoradiotherapy) 5. Prior staging with CT and PET-CT 6. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 7. Clinical staging of T1-T4, N0-N3, M0 disease 8. Adenocarcinoma or squamous cell carcinoma (SCC) histopathological cell type Exclusion Criteria: 9. Recurrent or residual disease 10. Distant metastatic disease detected before EUS. 11. Previous oesophagectomy or oesophageal radiotherapy 12. Unable to undergo EUS examination. 13. Concurrent malignancy e.g., second primary tumour 14. Other histopathological cell type

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Oesophageal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

esophageal cancer Esophageal Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Oesophageal cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    13 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cambridge University NHS Foundation Trust

    RECRUITING

    Cambridge, United Kingdom

  • Cardiff and Vale UHB

    RECRUITING

    Cardiff, United Kingdom

  • Castle Hill Hospital

    RECRUITING

    Hull, United Kingdom

  • Cwm Taf UHB

    RECRUITING

    Abercynon, United Kingdom

  • Glasgow Royal Infirmary

    RECRUITING

    Glasgow, United Kingdom

  • Guy's and St Thomas' NHS Foundation Trust

    RECRUITING

    London, United Kingdom

  • Imperial College Healthcare NHS Trust

    RECRUITING

    London, United Kingdom

  • Queen's Medical Centre, Nottingham

    RECRUITING

    Nottingham, United Kingdom

  • Royal Bournemouth Hospital

    TERMINATED

    Bournemouth, United Kingdom

  • Royal Cornwall Hospital

    RECRUITING

    Truro, United Kingdom

  • Salford Royal Hospital

    RECRUITING

    Salford, United Kingdom

  • Singleton Hospital, Swansea

    RECRUITING

    Swansea, United Kingdom

  • University Hospital Southampton

    RECRUITING

    Southampton, United Kingdom

  • Velindre University NHS Trust

    RECRUITING

    Cardiff, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.